<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072968</url>
  </required_header>
  <id_info>
    <org_study_id>P09-09 / BF2.649</org_study_id>
    <nct_id>NCT01072968</nct_id>
  </id_info>
  <brief_title>BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.</brief_title>
  <acronym>HAROSA2</acronym>
  <official_title>Efficacy and Safety of BF2.649 in Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea (OSA) Refusing the Nasal Continuous Positive Airway Pressure (nCPAP) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter randomized double blind study versus placebo during 12 weeks with at first, an
      escalating dose period followed by stable dose period at the selected dose.

      This double-blind period can be followed by a 9 months open-label period if the patient
      wishes to continue with the study product.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first period (12 weeks double blind period) will aim at demonstrating the efficacy and
      safety of BF2.649 by verifying whether the results of BF2.649 are superior to those of
      placebo.

      The aim of the second period (open label extension phase) will be to assess the long-term
      tolerance, as well as the maintenance of the BF2.649 efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ESS (Epworth Sleepiness Scale) change from baseline</measure>
    <time_frame>From baseline to week 12 and week 51</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">268</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Excessive Daytime Sleepiness</condition>
  <arm_group>
    <arm_group_label>BF2.649</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BF2.649 capsules dosed at 5 mg, 10 mg, 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules of placebo containing lactose with low, medium and high dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>1 capsule per day in the morning before the breakfast</description>
    <arm_group_label>BF2.649</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule per day in the morning before the breakfast</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with OSA still complaining EDS,refusing nCPAP

          -  ESS score â‰¥ 12

        Exclusion Criteria:

          -  Patients suffering from insomnia without OSA

          -  Co-existing narcolepsy

          -  Patient with sleep debt not due to OSA

          -  Acute or chronic severe disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyne De Paillette, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bioprojet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multicenter</keyword>
  <keyword>Randomized</keyword>
  <keyword>Double-blind</keyword>
  <keyword>Efficacy and safety study</keyword>
  <keyword>BF2.649 versus placebo</keyword>
  <keyword>Patients suffering from Obstructive Sleep Apnea</keyword>
  <keyword>Complaining from Excessive Daytime Sleepiness</keyword>
  <keyword>Refusing nasal Continuous Positive Airway Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

